Ventana shares soar on hostile $3B bid

Shares of Ventana Medical Systems surged this morning after investors reacted to Roche's $3 billion hostile takeover bid. Roche's $75 per share offer reflected a 44 percent premium on Ventana stock. It also represented another ambitious step into diagnostics work for Roche. The pharma giant has acquired 454 Life Sciences, Bioveris and Nimblegen in the last few months and says it may make other acquisitions in the same space. Roche says it made a number of friendly overtures to Ventana's board, but was rejected each time. Maybe saying "no" was just the right approach to fixing a higher price.

- check out the AFX report
- and here's the report from TheStreet

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.